Massachusetts Financial Services Co. MA Has $20.47 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Massachusetts Financial Services Co. MA increased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report) by 0.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 665,118 shares of the specialty pharmaceutical company’s stock after purchasing an additional 599 shares during the period. Massachusetts Financial Services Co. MA owned 2.04% of Collegium Pharmaceutical worth $20,472,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in shares of Collegium Pharmaceutical by 2.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock worth $31,987,000 after buying an additional 29,529 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at $1,179,000. Johnson Investment Counsel Inc. acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $257,000. BNP Paribas Financial Markets lifted its stake in shares of Collegium Pharmaceutical by 119.6% in the 4th quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock valued at $4,511,000 after purchasing an additional 79,823 shares during the period. Finally, Versor Investments LP boosted its position in shares of Collegium Pharmaceutical by 14.2% in the 4th quarter. Versor Investments LP now owns 10,579 shares of the specialty pharmaceutical company’s stock worth $326,000 after purchasing an additional 1,316 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Piper Sandler downgraded Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a report on Friday, May 10th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Needham & Company LLC lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Finally, Truist Financial upped their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $39.00.

Check Out Our Latest Report on COLL

Insiders Place Their Bets

In related news, Director Garen G. Bohlin sold 28,985 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $32.47 on Friday. The stock has a 50 day simple moving average of $37.13 and a 200 day simple moving average of $32.68. Collegium Pharmaceutical, Inc. has a 52-week low of $20.83 and a 52-week high of $40.95. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The firm has a market capitalization of $1.06 billion, a PE ratio of 13.53 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLLGet Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The firm had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

(Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Further Reading

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.